Compare iShares MSCI Australia ETF (EWA) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Pfizer Inc — how do they compare? iShares MSCI Australia ETF trades at $28.27 (market cap $1.19B), while Pfizer Inc trades at $27.77 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 134.1× iShares MSCI Australia ETF's market cap, and Pfizer Inc pays a 6.14% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 63 Days and Pfizer Inc for 158 Days on average.
| EWA | PFE | |
|---|---|---|
Market Cap | $1.19B | $159.59B |
Volume | 2,714,198 | 30,937,010 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $29.02 |
52-Week Low | $24.95 | $23.67 |
Typical Hold Time | 63 Days | 158 Days |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Australia ETF (EWA) trades at $28.23, down 1.12% amid bearish technical signals and mixed institutional activity. Recent news highlights Australia's stock market hitting three-month lows due to inflation concerns from rising oil prices, though some analysts see upside potential given the country's commodity-driven economy. Technical indicators show selling pressure with moving averages signaling bearish momentum while oscillators remain neutral.
EWA faces near-term headwinds from Australian market volatility and inflation worries, but long-term prospects remain tied to global commodity demand. The ETF's commodity exposure provides diversification benefits, though investors should monitor Australian economic conditions and Federal Reserve policy impacts. Risk-reward appears balanced with technical resistance at $29 and support at $28.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
